{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:50:15Z","timestamp":1791942615288,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"DOI":"10.1186\/s12903-024-04948-6","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T11:02:21Z","timestamp":1730890941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic effects of acyclovir and acyclovir-clobetasol nanofibers vs. cream formulation for recurrent herpes labialis"],"prefix":"10.1186","volume":"24","author":[{"given":"Shahla","family":"Mirzaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Golestan","family":"Nejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Khozaimeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solmaz","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Loqmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"issue":"1","key":"4948_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/v15010225","volume":"15","author":"D Gopinath","year":"2023","unstructured":"Gopinath D, et al. A Comprehensive Overview of Epidemiology, Pathogenesis and the management of herpes Labialis. Viruses. 2023;15(1):225.","journal-title":"Viruses"},{"key":"4948_CR2","doi-asserted-by":"crossref","unstructured":"La Selva A et al. Treatment of herpes labialis by photodynamic therapy: study protocol clinical trial (SPIRIT compliant). Medicine, 2020. 99(12).","DOI":"10.1097\/MD.0000000000019500"},{"issue":"2","key":"4948_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/v15020439","volume":"15","author":"R Tayyar","year":"2023","unstructured":"Tayyar R, Ho D. Herpes Simplex Virus and Varicella Zoster Virus infections in Cancer patients. Viruses. 2023;15(2):439.","journal-title":"Viruses"},{"key":"4948_CR4","doi-asserted-by":"publisher","first-page":"205873842093309","DOI":"10.1177\/2058738420933099","volume":"34","author":"X-X Mei","year":"2020","unstructured":"Mei X-X, et al. Herpes simplex virus type I\u2013infected disorders alter the balance between Treg and Th17 cells in recurrent herpes labialis patients. Int J ImmunoPathol Pharmacol. 2020;34:2058738420933099.","journal-title":"Int J ImmunoPathol Pharmacol"},{"issue":"2","key":"4948_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/vaccines11020206","volume":"11","author":"D Sharma","year":"2023","unstructured":"Sharma D, et al. An insight into current treatment strategies, their limitations, and ongoing developments in vaccine technologies against herpes simplex infections. Vaccines. 2023;11(2):206.","journal-title":"Vaccines"},{"issue":"11","key":"4948_CR6","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/j.1468-3083.2011.04348.x","volume":"26","author":"B Dr\u00e9no","year":"2012","unstructured":"Dr\u00e9no B, et al. Patients\u2019 profile, burden of disease and quality of life in recurrent herpes labialis: a survey conducted in USA and France. J Eur Acad Dermatol Venereol. 2012;26(11):1458\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4948_CR7","doi-asserted-by":"crossref","unstructured":"Chen F, et al. Efficacy and safety of Nucleoside antiviral drugs for treatment of recurrent herpes Labialis: a systematic review and Meta-analysis. Journal of Oral Pathology & Medicine; 2016.","DOI":"10.1111\/jop.12534"},{"key":"4948_CR8","doi-asserted-by":"crossref","unstructured":"ROSA MID, et al. Efficacy of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of herpes labialis: a systematic review. Volume 87. Anais da Academia Brasileira de Ci\u00eancias; 2015. pp. 1415\u201320.","DOI":"10.1590\/0001-3765201520140701"},{"issue":"1","key":"4948_CR9","doi-asserted-by":"publisher","first-page":"18953","DOI":"10.1038\/s41598-020-76151-w","volume":"10","author":"L Kannan","year":"2020","unstructured":"Kannan L, et al. Anti-herpes virus activity of the carnivorous botanical, Sarracenia purpurea. Sci Rep. 2020;10(1):18953.","journal-title":"Sci Rep"},{"issue":"7","key":"4948_CR10","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.3390\/ijms23073431","volume":"23","author":"A Majewska","year":"2022","unstructured":"Majewska A, Mlynarczyk-Bonikowska B. 40 years after the registration of acyclovir: do we need new anti-herpetic drugs? Int J Mol Sci. 2022;23(7):3431.","journal-title":"Int J Mol Sci"},{"key":"4948_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coviro.2016.01.013","volume":"18","author":"A Birkmann","year":"2016","unstructured":"Birkmann A, Zimmermann H. HSV antivirals\u2013current and future treatment options. Curr Opin Virol. 2016;18:9\u201313.","journal-title":"Curr Opin Virol"},{"issue":"3","key":"4948_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1468-3083.2008.03047.x","volume":"23","author":"C Hull","year":"2009","unstructured":"Hull C, et al. Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. J Eur Acad Dermatol Venereol. 2009;23(3):263\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4948_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4103\/0378-6323.178903","volume":"82","author":"AB Mehta","year":"2016","unstructured":"Mehta AB, et al. Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 2016;82:371.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"4948_CR14","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jaad.2005.12.028","volume":"54","author":"SE Jacob","year":"2006","unstructured":"Jacob SE, Steele T. Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity. J Am Acad Dermatol. 2006;54(4):723\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"4948_CR15","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/jps.10402","volume":"92","author":"DE Mager","year":"2003","unstructured":"Mager DE, Moledina N, Jusko WJ. Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. J Pharm Sci. 2003;92(7):1521\u20135.","journal-title":"J Pharm Sci"},{"issue":"2","key":"4948_CR16","first-page":"187","volume":"74","author":"NK Devaraj","year":"2019","unstructured":"Devaraj NK, et al. Topical corticosteroids in clinical practice. Med J Malaysia. 2019;74(2):187\u20139.","journal-title":"Med J Malaysia"},{"issue":"1","key":"4948_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12879-015-0824-0","volume":"15","author":"N Arain","year":"2015","unstructured":"Arain N, Paravastu SC, Arain MA. Effectiveness of topical corticosteroids in addition to antiviral therapy in the management of recurrent herpes labialis: a systematic review and meta-analysis. BMC Infect Dis. 2015;15(1):82.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"4948_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4103\/2231-4040.101006","volume":"3","author":"S Ansari","year":"2012","unstructured":"Ansari S, Farha M, Islam. Influence of nanotechnology on herbal drugs: a review. J Adv Pharm Tech Res. 2012;3(3):142.","journal-title":"J Adv Pharm Tech Res"},{"key":"4948_CR19","unstructured":"Mathur M, Vyas G. Role of nanoparticles for production of smart herbal drug\u2009\u2013\u2009An overview. 2013."},{"issue":"8","key":"4948_CR20","doi-asserted-by":"publisher","first-page":"2004014","DOI":"10.1002\/advs.202004014","volume":"8","author":"P Makvandi","year":"2021","unstructured":"Makvandi P, et al. Drug delivery (nano) platforms for oral and dental applications: tissue regeneration, infection control, and cancer management. Adv Sci. 2021;8(8):2004014.","journal-title":"Adv Sci"},{"issue":"5","key":"4948_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.biomaterials.2007.10.012","volume":"29","author":"JS Choi","year":"2008","unstructured":"Choi JS, Leong KW, Yoo HS. In vivo wound healing of diabetic ulcers using electrospun nanofibers immobilized with human epidermal growth factor (EGF). Biomaterials. 2008;29(5):587\u201396.","journal-title":"Biomaterials"},{"issue":"1","key":"4948_CR22","doi-asserted-by":"publisher","first-page":"101778","DOI":"10.1016\/j.jebdp.2022.101778","volume":"23","author":"KH Koe","year":"2023","unstructured":"Koe KH, et al. COMPARATIVE EFFICACY OF ANTIVIRAL AGENTS FOR PREVENTION AND MANAGEMENT OF HERPES LABIALIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. J Evidence-Based Dent Pract. 2023;23(1):101778.","journal-title":"J Evidence-Based Dent Pract"},{"issue":"5","key":"4948_CR23","first-page":"331","volume":"70","author":"A Astani","year":"2015","unstructured":"Astani A, Albrecht U, Schnitzler P. Piroxicam inhibits herpes simplex virus type 1 infection in vitro. Die Pharmazie-An Int J Pharm Sci. 2015;70(5):331\u20136.","journal-title":"Die Pharmazie-An Int J Pharm Sci"},{"issue":"4","key":"4948_CR24","doi-asserted-by":"publisher","first-page":"e6961","DOI":"10.1016\/j.jaad.2010.08.012","volume":"64","author":"CM Hull","year":"2011","unstructured":"Hull CM, et al. Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial. J Am Acad Dermatol. 2011;64(4):e6961\u201311.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4948_CR25","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1128\/AAC.02150-13","volume":"58","author":"CM Hull","year":"2014","unstructured":"Hull CM, et al. Novel composite efficacy measure to demonstrate the rationale and efficacy of combination antiviral-anti-inflammatory treatment for recurrent herpes simplex labialis. Antimicrob Agents Chemother. 2014;58(3):1273\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"4948_CR26","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1172\/JCI136225","volume":"130","author":"JI Cohen","year":"2020","unstructured":"Cohen JI. Herpesvirus latency. J Clin Investig. 2020;130(7):3361\u20139.","journal-title":"J Clin Investig"},{"issue":"3","key":"4948_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0026-2862(03)00011-6","volume":"65","author":"A Sommer","year":"2003","unstructured":"Sommer A, et al. Vasoconstrictive effect of topical applied corticosteroids measured by laser doppler imaging and reflectance spectroscopy. Microvasc Res. 2003;65(3):152\u20139.","journal-title":"Microvasc Res"},{"issue":"4","key":"4948_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/095632020301400405","volume":"14","author":"JG Harmenberg","year":"2003","unstructured":"Harmenberg JG, et al. ME-609: a treatment for recurrent herpes simplex virus infections. Antiviral Chem Chemother. 2003;14(4):205\u201315.","journal-title":"Antiviral Chem Chemother"},{"issue":"6","key":"4948_CR29","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1086\/315528","volume":"181","author":"SL Spruance","year":"2000","unstructured":"Spruance SL, McKeough MB. Combination treatment with famciclovir and a topical corticosteroid gel versus famciclovir alone for experimental ultraviolet radiation-induced herpes simplex labialis: a pilot study. J Infect Dis. 2000;181(6):1906\u201310.","journal-title":"J Infect Dis"},{"issue":"6","key":"4948_CR30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.addr.2011.01.012","volume":"63","author":"TW Prow","year":"2011","unstructured":"Prow TW, et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011;63(6):470\u201391.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"4948_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2340\/00015555-0806","volume":"90","author":"J Harmenberg","year":"2010","unstructured":"Harmenberg J, \u00d6berg B, Spruance S. Prevention of ulcerative lesions by episodic treatment of recurrent herpes labialis: a literature review. Acta dermato-venereologica. 2010;90(2):122\u201330.","journal-title":"Acta dermato-venereologica"},{"issue":"2","key":"4948_CR32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/oem.59.2.140","volume":"59","author":"E Ernst","year":"2002","unstructured":"Ernst E, Fugh-Berman A. Complementary and alternative medicine: what is it all about? Occup Environ Med. 2002;59(2):140\u20134.","journal-title":"Occup Environ Med"},{"issue":"8","key":"4948_CR33","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.biomaterials.2005.08.004","volume":"27","author":"KS Rho","year":"2006","unstructured":"Rho KS, et al. Electrospinning of collagen nanofibers: effects on the behavior of normal human keratinocytes and early-stage wound healing. Biomaterials. 2006;27(8):1452\u201361.","journal-title":"Biomaterials"},{"issue":"3","key":"4948_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijbiomac.2011.04.005","volume":"49","author":"K Shalumon","year":"2011","unstructured":"Shalumon K, et al. Sodium alginate\/poly (vinyl alcohol)\/nano ZnO composite nanofibers for antibacterial wound dressings. Int J Biol Macromol. 2011;49(3):247\u201354.","journal-title":"Int J Biol Macromol"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-024-04948-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-024-04948-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-024-04948-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T11:04:06Z","timestamp":1730891046000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcoralhealth.biomedcentral.com\/articles\/10.1186\/s12903-024-04948-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4948"],"URL":"https:\/\/doi.org\/10.1186\/s12903-024-04948-6","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"25 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from patients who met the criteria for entering the study. The ethics committee of Isfahan University of Medical Sciences, Isfahan, Iran, verified the current study with the ethical code: IR.MUI.REC.1397.3.081.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study adheres to CONSORT guidelines.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"CONSORT Guideline"}}],"article-number":"1348"}}